| scholarly article | Q13442814 |
| editorial | Q871232 |
| P2093 | author name string | Woo Jin Chung | |
| P2860 | cites work | Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. | Q50568686 |
| Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. | Q50580153 | ||
| Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. | Q50588396 | ||
| Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin | Q27481147 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
| Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group | Q29620719 | ||
| Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update | Q33303530 | ||
| Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy | Q33372925 | ||
| Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis. | Q37975254 | ||
| Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. | Q42980478 | ||
| Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa | Q42981515 | ||
| Antiviral action of ribavirin in chronic hepatitis C. | Q42983488 | ||
| Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate | Q42999332 | ||
| Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. | Q43000537 | ||
| Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin | Q43032187 | ||
| Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment | Q43034816 | ||
| Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. | Q43035294 | ||
| Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. | Q43040369 | ||
| Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. | Q43046858 | ||
| Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon | Q43048289 | ||
| Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment | Q44901526 | ||
| Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. | Q44911029 | ||
| Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus | Q45399483 | ||
| Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I | Q45752944 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | ribavirin | Q421862 |
| chronic hepatitis C | Q55779873 | ||
| P304 | page(s) | 268-271 | |
| P577 | publication date | 2012-09-25 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients | |
| P478 | volume | 18 |
Search more.